AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01548391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX-1171
Description: 20mg, 200mg, 500mg
Study NCT02154737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
Study NCT02154737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be administered orally on Days 2-4 and Days 16-18 of a 28-day cycle in serial cohorts with doses of 750mg, 1000mg, 1250mg, 1500mg, 1750mg, and 2000mg.
Study NCT02359422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Media Aware-Sexual Health
Description: 10-lesson middle school, comprehensive sexual health media literacy education program. Each lesson take approximately 50 minutes to teach and will be taught every school day for 2 weeks.
Study NCT00573937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.
Study NCT00573937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Oral slow-release morphine 15 mg every 8 hours, and oral immediate-release morphine 10 mg every 4 hours as needed for breakthrough pain.
Study NCT00689780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1940
Description: Oral solution Multiple ascending dose given orally once daily at day 1-12
Study NCT00689780 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: Oral solution given orally once daily on day -1 and day 14
Study NCT04051281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter
Description: Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)
Study NCT04051281 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Letter
Description: Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)
Study NCT01127035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sublingual immunotherapy
Study NCT01127035 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03898258 — intervention group
Intervention type: OTHER
Intervention: Qualiveen full version
Description: Qualiveen full version questionnaire with 40 questions for assessing the quality of life in relation to bladder dysfunction in persons with neurogenic bladder
Study NCT03898258 — intervention group
Intervention type: OTHER
Intervention: Qualiveen short-form
Description: Qualiveen short-form questionnaire with 8 questions for assessing the quality of life in relation to bladder dysfunction in persons with neurogenic bladder
Study NCT01614769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride 2 mg
Description: One placebo tablet and one 2-mg glimepiride tablet taken on Day -1 and Day 1 of the three treatment periods.
Study NCT04204837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given on Day 1 of every 14-day cycle (Q2W) at a dose of 240 mg as an IV infusion until progression, unacceptable toxicity or discontinuation for other reasons for up to 2 years.
Study NCT04204837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Relatlimab
Description: Patients wil receive a fixed-dose combination of nivolumab 480 mg and relatlimab 160 mg by intravenous infusion every four weeks (Q4W) (Group 2) for up to two years after initial dosing or until PD - or absence of investigator-assessed clinical benefit
Study NCT02387138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1: Administered orally twice daily from day 1 for 7 consecutive days followed by a 7-day recovery period in a 14-day cycle.~The starting dose of S-1 will be two levels below the recommended dose defined in SIRI (20 mg/m² BID minimum) with a cohort dose escalation by 5 mg/m² increments (5 dose levels).
Study NCT02387138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan : fixed dose of 180 mg/m² IV over 90 minutes on d1 of every cycle
Study NCT02387138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin : fixed dose of 85 mg/m² over 120 minutes on d1 of every cycle
Study NCT02387138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G-csf
Description: G-csf : d8 to d13 systematically
Study NCT00809354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: IV doses of placebo (to match tanezumab) every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
Study NCT00809354 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: IV tanezumab 5 mg every 8 weeks (through Week 48) and oral placebo for NSAID BID from Weeks 2 through 56
Study NCT00809354 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: IV tanezumab 10 mg every 8 weeks (through Week 56) and oral placebo for NSAID BID from Weeks 2 through 56
Study NCT00809354 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: IV tanezumab 5 mg every 8 weeks (through Week 48)
Study NCT00809354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID
Description: Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
Study NCT00809354 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: IV tanezumab 10 mg every 8 weeks (through Week 48)
Study NCT02213640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: Anodal tDCS over the primary motor cortex. Stimulation intensity of 1mA during 20 minutes (5 consecutive sessions during one week).
Study NCT02213640 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control: placebo stimulation
Description: electrode of sham tDCS over the primary motor cortex during 20 minutes (5 consecutive sessions during one week).
Study NCT04701710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin / Iota-Carrageenan
Description: The EG received Ivermectin orally 2 drops of 6 mg = 12 mg every 7 days, and Iota-Carrageenan 6 sprays per day for 4 weeks.
Study NCT01701921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 75mg
Description: Pregabalin 75mg by mouth one hour before surgery
Study NCT01701921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin 150 mg
Description: pregabalin 150mg by mouth one hour before surgery
Study NCT03420820 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacterial Culture Swab
Description: Culture swabs will be obtained before application of PI and after injection.
Study NCT01701921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill designed to mimic pregabalin capsule, by mouth one hour before surgery
Study NCT01614769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride 4 mg
Description: Two 2-mg glimepiride tablets taken on Day -1 and Day 1 of the three treatment periods.
Study NCT00618787 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: COPA AMD (note: name is not an acronym)
Description: Foam dressing impregnated with Polyhexamethylene Biguanide
Study NCT00618787 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: COPA (note: name is not an acronym)
Description: Regular foam dressing without PHMB
Study NCT03436667 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: Lung volumes will be measured using spirometry.
Study NCT03436667 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Reaction Time
Description: PVT-192 Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurement.
Study NCT04194242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC96719 tablets
Description: 0.1、0.2、0.5、1、2、3、4 mg HEC96719 tablet in day1
Study NCT04194242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: 0.1、0.2、0.5、1、2、3、4 mg Placebo tablet in day1
Study NCT02760342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: Oral
Study NCT02760342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral
Study NCT00813020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Comparison of different formulations of the drug, semaglutide: Formulation 1 administered in equimolar doses
Study NCT00813020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Comparison of different formulations of the drug, semaglutide: Formulation 2 administered in equimolar doses
Study NCT00813020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Comparison of different formulations of the drug, semaglutide: Formulation 3 administered in equimolar doses
Study NCT04348643 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CEA CAR-T cells
Description: CEA-CAR-T cells will be administered intravenously.
Study NCT00254761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Study NCT04486716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Investigational drug will be provided in an autoinjector for subcutaneous administration containing 20 mg ofatumumab (20 mg/0.4 ml)
Study NCT00254761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis
Study NCT00693849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10 mg/day as a single dose, increased to max 20 mg/day
Study NCT00693849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: 50 mg/day as a single dose, increased to max of 200 mg/day
Study NCT00693849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine-XR
Description: 75 mg/day given once daily; increased to 150-225 mg/day
Study NCT03493620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device arm
Description: Make a gastric tube (endoscopic sleeve gastroplasty) using the Apollo Overstitch suturing device through endoscopy.
Study NCT03493620 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham arm
Description: Group II will be conducted identically to Group I except for the procedure itself, and only the endoscopist, that is the researcher, will be aware of which group each patient belongs to.
Study NCT01614769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoglycemic Clamp
Description: On Day 1 of the three treatment periods, 180 minutes after drug treatment, a fixed-rate insulin infusion is combined with a variable-rate dextrose infusion to maintain plasma glucose concentrations at close to 50 mg/dL for 30 minutes.
Study NCT01806077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PZ-128
Description: Sequential single-dose escalation; 1 to 2 hour continuous intravenous infusion
Study NCT03727321 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplant
Description: Fecal microbiome transplant (FMT): 50grams of FMT from a single, universal donor will be administered in 20-30 capsules taken by mouth.
Study NCT02505295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Selenium
Description: 4 vials selenase stat and 2 vials daily for 5 days
Study NCT04129398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir tablet
Description: A single 240 mg tablet or two 240 mg tablets letermovir administered orally, once daily for 28 weeks
Study NCT04129398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir IV
Description: IV solution of 240 mg (one vial) or 480 mg (2 vials) letermovir in 250 mL infused over 60 minutes, once daily for 28 weeks
Study NCT04366310 — intervention group
Intervention type: DEVICE
Intervention: capillary refill index
Description: a waveform analysis method using a pulse oximeter to assess peripheral perfusion
Study NCT04366310 — intervention group
Intervention type: PROCEDURE
Intervention: rewarming
Description: warming fingertip skin temperature using an instant hot pack
Study NCT02505295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Normal saline infusion like intervention group
Study NCT03727321 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber
Description: A combination of soluble corn fiber (PROMITOR®: Tate\&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), and Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS) for a total of 6 weeks (men 33g/day; women 27g/day)
Study NCT03727321 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cellulose
Description: Placebo will consist of cellulose powder (Microcrystalline cellulose:Blanver) in foil packets.
Study NCT03434574 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
Study NCT03434574 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aronia extract
Description: Powdered extract obtained from aronia berries (Aronia melanocarpa).
Study NCT03727321 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: Placebo will consist of cellulose powder (Microcrystalline cellulose:Blanver) in foil packets.
Study NCT04307147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral capecitabine (at a dose of 1250 mg/m², twice per day, on days 1 to 14) every 3 weeks for 4 cycles.
Study NCT04307147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Intravenous vinorelbine (at a dose of 25 mg/m² on day 1, day 8) every 3 weeks for 4 cycles.
Study NCT03437772 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mindfulness Cognitive Behavioral Therapy program
Description: 16 simultaneous-but-separate therapy sessions for parents and children.
Study NCT03272334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER2 BATs with Pembrolizumab
Description: 8 infusions of HER2 BATs with 1-3 infusions of Pembrolizumab
Study NCT02953431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP will be administered with a CPAP machine
Study NCT02953431 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CPAP
Description: CPAP will be administered with a CPAP machine
Study NCT03286868 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: Total Knee Arthroplasty
Study NCT03286868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty with Verasense sensor
Description: Total Knee Arthroplasty with Verasense sensor
Study NCT00936936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1800 mg/m\^2 IV over 3 hours on Days -5 to Day -2.
Study NCT00936936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 300 mg/m\^2 IV over 2 hours on Day -5.
Study NCT00936936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 50 mg/m\^2 IV over 15 minutes on Days -4 to Day -2.
Study NCT00936936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Cycle 1: 333 mg/m\^2 IV over 2 hours on Days -4 to -2.~Cycle #2: 300 mg/m\^2 IV over 2 hours on Days -6 to -3.
Study NCT00936936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 3,000 mg/m\^2 per day in 96-hour continuous infusion, starting 30 minutes prior to the first dose of ifosfamide, on Days -6 to -4.
Study NCT00936936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 3,000 mg/m\^2 IV over 6 hours on Days -6 to -3
Study NCT00936936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 200 mg/m\^2 IV over 3 hours, every 12 hours on Days -6 to -4.
Study NCT00936936 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Stem cell infusion on Day 0.
Study NCT00499447 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Study NCT00499447 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT03062319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Anticoagulant
Description: warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban
Study NCT03062319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet Drug
Description: aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol
Study NCT03413995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Continuous dosing
Study NCT03907202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daily injection of KBP/placebo for up to 28 days
Description: Daily sub-cutaneous injection of KBP-089/Placebo into a lifted skin fold of the abdominal wall.The injection will be administered in the morning before breakfast.
Study NCT03907202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Daily injection of KBP/placebo for up to 28 days
Description: Daily sub-cutaneous injection of KBP-089/Placebo into a lifted skin fold of the abdominal wall.The injection will be administered in the morning before breakfast.
Study NCT04255381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)
Description: Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)
Study NCT02759510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Hypotension (systolic BP \<80% of baseline) will be treated with intravenous boluses of norepinephrine 2 μg.
Study NCT02759510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Hypotension (systolic BP \<80% of baseline) will be treated with intravenous boluses of phenylephrine 40 μg.
Study NCT00963638 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MagTabSR
Description: MagTabSR/placebo 168 mgs BID for 6 six weeks
Study NCT00963638 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MagTabSR/placebo 168 mgs BID for 6 six weeks
Study NCT04161482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 80 mg (8 mg/mL)
Description: Furoscix will be administered as a subcutaneous infusion.
Study NCT00939185 — intervention group
Intervention type: DRUG
Intervention: Azithromycin
Description: Zithromax was dispensed according to the Summary of Product Characteristics (SPC) as either a tablet or suspension. Zithromax was administered as a total dose of 30 mg/kg which was given as single daily doses of 10 mg/kg for 3 days, or as a 5 day dose starting with 10 mg/kg on Day 1, then 5 mg/kg on Days 2-5.
Study NCT03923088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: jacobson's progressive muscle relaxation technique
Description: This involves tensing specific muscle groups for 5-7 seconds, followed by 20 seconds of relaxation. The method can be demonstrated chairside, and should be practiced and rehearsed by the patient at home. Four major muscle groups are commonly tensed and relaxed. These are: 1) feet, calves, thighs, and buttocks; 2) hands, forearms, and biceps; 3) chest, stomach, and lower back; and 4) head, face, throat, and shoulders
Study NCT03923088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: audio-visual distraction technique
Description: audiovisual distraction not only leads to full involvement of scenes (visual and auditory), but it also induces a positive emotional reaction resulting in a relaxed experience.
Study NCT04414943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: For women in this group, active drug (s-ketamine 0.2 mg/kg in 20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.
Study NCT04414943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For women in this group, placebo (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.
Study NCT02593630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unicirc circumcision
Description: Unicirc circumcision under topical (EMLA) anaesthesia, wound sealing with cyanoacrylate tissue adhesive
Study NCT02956473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supine MRI
Study NCT03610282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Methylphenidate
Description: Subjects will receive a bolus of IV methylphenidate during propofol infusion at one of the study visits.
Study NCT02956473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Therapy (NAT)